Renovaro Inc.

Equities

RENB

US29350E1047

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.7 ^USD	-13.71%		-26.09%	-46.37%

Apr. 24	Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics	MT
Apr. 18	Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	CI

Enochian Biosciences : Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

October 12, 2021 at 07:02 pm EDT

Enochian BioSciences

Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS and Oncology.

Attachments

Original document
Permalink

Disclaimer

Enochian Biosciences Inc. published this content on 12 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2021 23:01:07 UTC.

Latest news about Renovaro Inc.

Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics	Apr. 24	MT
Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	Apr. 18	CI
Renovaro Inc. Appoints Simon Tarsh as Interim Chief Financial Officer	Mar. 13	CI
Renovaro Inc. Announces Resignation of Luisa Puche as Chief Financial Officer, Effective as of March 21, 2024	Mar. 05	CI
Renovaro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Renovaro Inc. Announces Board Changes	Feb. 14	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 14	MT
Sector Update: Health Care	Feb. 14	MT
Renovaro Shares Jump After Response to Short Seller Hindenburg's Report	Feb. 14	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 13	MT
Renovaro's GEDi Cube Agrees to Acquire 75% Stake in Cyclomics	Feb. 13	MT
Renovaro Shares Tumble Following Report From Short-Seller Hindenburg	Feb. 13	MT
Renovaro Biosciences Inc. completed the acquisition of GEDi Cube Intl Ltd.	Feb. 12	CI
Top Premarket Gainers	Feb. 07	MT
Renovaro Biosciences' Shareholders Approve Share Issuance for Merger Deal With GEDi Cube	Jan. 25	MT
North American Morning Briefing : Stock Futures -2-	Nov. 16	DJ
Renovaro Biosciences Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors	23-10-11	CI
Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors	23-10-10	CI
North American Morning Briefing : Stock Futures, -2-	23-10-05	DJ
Renovaro Biosciences Inc. announced that it expects to receive $2 million in funding	23-10-04	CI
Renovaro Biosciences Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-02	CI
Sector Update: Health Care Stocks Declining Friday Afternoon	23-09-29	MT
Renovaro Biosciences, GEDi Cube Enter Stock-for-stock Acquisition Deal	23-09-29	MT
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ

Chart Renovaro Inc.

Duration

Period

More charts

Company Profile

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVARO INC.	-46.37%	283M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs